InMed Pharmaceuticals Secures $5 Million Through Private Placement Priced At-the-Market Under Nasdaq Rules

Reuters

07-01

InMed Pharmaceuticals Secures $5 Million Through Private Placement Priced At-the-Market Under Nasdaq Rules

InMed Pharmaceuticals Inc., a company specializing in the development of small molecule drug candidates for diseases with high unmet medical needs, has announced a $5 million private placement. The company has entered into definitive agreements with a single institutional investor for the issuance and sale of 1,952,363 common shares and short-term preferred investment options to purchase the same number of common shares. These shares are priced at $2.561 each, with the associated options exercisable at $2.436 per share. H.C. Wainwright & Co. served as the exclusive placement agent for this offering. The gross proceeds are expected to be approximately $5 million, with potential additional proceeds of $4.75 million if the options are fully exercised. The company plans to use the funds to advance its pipeline development, support sales through its subsidiary BayMedica LLC, and for general working capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-059673), on June 30, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2548010568"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2548010568\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2548010568?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-01 04:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548010568","market":"fut","top_or_hot":-1,"title":"InMed Pharmaceuticals Secures $5 Million Through Private Placement Priced At-the-Market Under Nasdaq Rules","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      InMed Pharmaceuticals Secures $5 Million Through Private Placement Priced At-the-Market Under Nasdaq Rules\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/INM\">InMed Pharmaceuticals Inc</a>., a company specializing in the development of small molecule drug candidates for diseases with high unmet medical needs, has announced a $5 million private placement. The company has entered into definitive agreements with a single institutional investor for the issuance and sale of 1,952,363 common shares and short-term preferred investment options to purchase the same number of common shares. These shares are priced at $2.561 each, with the associated options exercisable at $2.436 per share. H.C. Wainwright &amp; Co. served as the exclusive placement agent for this offering. The gross proceeds are expected to be approximately $5 million, with potential additional proceeds of $4.75 million if the options are fully exercised. The company plans to use the funds to advance its pipeline development, support sales through its subsidiary BayMedica LLC, and for general working capital.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-059673), on June 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InMed Pharmaceuticals Secures $5 Million Through Private Placement Priced At-the-Market Under Nasdaq Rules</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInMed Pharmaceuticals Secures $5 Million Through Private Placement Priced At-the-Market Under Nasdaq Rules\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-01 04:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      InMed Pharmaceuticals Secures $5 Million Through Private Placement Priced At-the-Market Under Nasdaq Rules\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/INM\">InMed Pharmaceuticals Inc</a>., a company specializing in the development of small molecule drug candidates for diseases with high unmet medical needs, has announced a $5 million private placement. The company has entered into definitive agreements with a single institutional investor for the issuance and sale of 1,952,363 common shares and short-term preferred investment options to purchase the same number of common shares. These shares are priced at $2.561 each, with the associated options exercisable at $2.436 per share. H.C. Wainwright &amp; Co. served as the exclusive placement agent for this offering. The gross proceeds are expected to be approximately $5 million, with potential additional proceeds of $4.75 million if the options are fully exercised. The company plans to use the funds to advance its pipeline development, support sales through its subsidiary BayMedica LLC, and for general working capital.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-059673), on June 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDLc1xdy5:1","article_id":"2548010568","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548010568","pubTimestamp":1751314598,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"InMed Pharmaceuticals Inc., a company specializing in the development of small molecule drug candidates for diseases with high unmet medical needs, has announced a $5 million private placement. The company has entered into definitive agreements with a single institutional investor for the issuance and sale of 1,952,363 common shares and short-term preferred investment options to purchase the same number of common shares. These shares are priced at $2.561 each, with the associated options exercisable at $2.436 per share. H.C. Wainwright & Co. served as the exclusive placement agent for this offering. The gross proceeds are expected to be approximately $5 million, with potential additional proceeds of $4.75 million if the options are fully exercised. The company plans to use the funds to advance its pipeline development, support sales through its subsidiary BayMedica LLC, and for general working capital.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","INM":"InMed Pharmaceuticals Inc"},"translate_title":"InMed Pharmaceuticals通过根据纳斯达克规则按市场定价的私募获得500万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INM":0.9},"content_text":"InMed Pharmaceuticals Secures $5 Million Through Private Placement Priced At-the-Market Under Nasdaq Rules\n    \n\nInMed Pharmaceuticals Inc., a company specializing in the development of small molecule drug candidates for diseases with high unmet medical needs, has announced a $5 million private placement. The company has entered into definitive agreements with a single institutional investor for the issuance and sale of 1,952,363 common shares and short-term preferred investment options to purchase the same number of common shares. These shares are priced at $2.561 each, with the associated options exercisable at $2.436 per share. H.C. Wainwright & Co. served as the exclusive placement agent for this offering. The gross proceeds are expected to be approximately $5 million, with potential additional proceeds of $4.75 million if the options are fully exercised. The company plans to use the funds to advance its pipeline development, support sales through its subsidiary BayMedica LLC, and for general working capital.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-059673), on June 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}